Family history of cancer is associated with poorer prognosis in oral squamous cell carcinoma

Abstract

Objective The purpose of this study was to investigate the prognostic value of the family history of cancer (FHC) in predicting survival and clinicopathological features in oral squamous cell carcinoma (OSCC) patients. Materials and Methods This single‐institution study utilized data from 610 patients undergoing surgery from 2014 to 2020 that was prospectively collected and cataloged for research purposes. All patients underwent standard surgery with/without radiotherapy or chemoradiotherapy. We statistically evaluated whether FHC was associated with changes in disease‐free survival (DFS) and disease‐specific survival (DSS). Results Among 610 patients, 141 (23.1%) reported a family history of cancer. The distribution of clinicopathological characteristics was balanced between FHC‐positive and FHC‐negative OSCC patients. FHC‐positive patients had decreased DFS (p = 0.005) and DSS (p = 0.018) compared to FHC‐negative patients. Conclusions FHC‐positive OSCC patients have a poorer prognosis. FHC positivity is an independent predictor of negative outcomes based on DFS and DSS. FHC should be a consideration in screening, evaluating, counseling, and treating OSCC patients.

Community Collage Service (KKN) student assistance to improve women's health by detecting breast cancer and cervical cancer in Amansari Village, Karawang Regency

“…Cancer has the potential to make middle and low economic families become poorer. [7][8][9] According to the Jamkesmas (Health Insurance for the Poor) report, it was shown that in 2012 cancer treatment ranked second after hemodialysis, reaching 144.7 billion rupiahs. 10 Although Breast Cancer and Cervical Cancer are the most common cancers in women today, early detection of both types of cancer can be done with inexpensive and simple or simple appropriate technology and improving the quality of treatment by early detection using the Clinical Breast Examine (CBE), better known as BSE for breast cancer, and IVA and Pap smear methods for cervical cancer will accelerate the handling of these two types of cancer, so that the prognosis will be better and the cost of treatment services can also be reduced.…”